缩写名/全名 |
FUTURE ONCOL
Future Oncology |
||||||||||||||||||||
ISSN号 | 1479-6694 | ||||||||||||||||||||
研究方向 | ONCOLOGY- | ||||||||||||||||||||
影响因子 | 2015:2.129, 2016:2.131, 2017:2.369, 2018:2.279, 2019:2.66, | ||||||||||||||||||||
出版国家 | ENGLAND | ||||||||||||||||||||
出版周期 | Monthly | ||||||||||||||||||||
年文章数 | 336 | ||||||||||||||||||||
出版年份 | 2005 | ||||||||||||||||||||
是否OA | No | ||||||||||||||||||||
审稿周期(仅供参考) | 偏慢,4-8周 |
||||||||||||||||||||
录用比例 | |||||||||||||||||||||
投稿链接 | http://www.futuremedicine.com/page/submitarticle | ||||||||||||||||||||
投稿官网 | http://www.futuremedicine.com/loi/fon | ||||||||||||||||||||
h-index | 60 | ||||||||||||||||||||
CiteScore |
|
||||||||||||||||||||
PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1479-6694%5BISSN%5D | ||||||||||||||||||||
中科院SCI期刊分区 ( 2018年新版本) |
|
||||||||||||||||||||
中科院SCI期刊分区 ( 2020年新版本) |
|
中国学者近期发表的论文 | |
1. | A breast one-patient panel of heterogeneous genomes reveals genetic alterations driving DCIS into invasive lesions. Author: Yang M1, Xu Z2,3, Zhang QZ4,5, Wang K1, Ji XY4,6, Xu J7, Zhang JY8, Niu G4,5. Journal: Future Oncol. 2019 May;15(14):1565-1576. doi: 10.2217/fon-2018-0555. Epub 2019 Mar 19. PubMed DOI |
2. | Early breast cancer patients benefit more from longer course chemotherapy: a matched-pair analysis. Author: Wang Y1, Yin W1, Lin Y1, Zhou L1, Du Y1, Yin K1, Lu J1. Journal: Future Oncol. 2019 May;15(15):1781-1789. doi: 10.2217/fon-2018-0666. Epub 2019 Mar 22. PubMed DOI |
3. | Associations of PIK3CA mutations with clinical features and prognosis in gastric cancer. Author: Shen X1, Zhao Y1, Chen X1, Sun H1, Liu M1, Zhang W1, Jiang F, Li P1. Journal: Future Oncol. 2019 Mar 28. doi: 10.2217/fon-2018-0335. [Epub ahead of print] PubMed DOI |
4. | GPX3 hypermethylation in gastric cancer and its prognostic value in patients aged over 60. Author: Zhou C1, Pan R1, Li B1, Huang T1, Zhao J1, Ying J2, Duan S1. Journal: Future Oncol. 2019 Apr;15(11):1279-1289. doi: 10.2217/fon-2018-0674. Epub 2019 Mar 29. PubMed DOI |
5. | Overexpression of EIF5A2 in upper urinary tract urothelial carcinoma is a new independent prognostic marker of survival. Author: Fang Y1, Cen JJ1, Cao JZ2, Huang Y1, Feng ZH1, Lu J1, Wei JH1, Chen ZH1, Liang YP1, Liao B3, Luo JH1, Chen W1. Journal: Future Oncol. 2019 Apr 1. doi: 10.2217/fon-2018-0748. [Epub ahead of print] PubMed DOI |
6. | High KCNQ1OT1 expression might independently predict shorter survival of colon adenocarcinoma. Author: Zhang K1, Yan J1, Yi B1, Rui Y1, Hu H1. Journal: Future Oncol. 2019 Apr;15(10):1085-1095. doi: 10.2217/fon-2018-0499. Epub 2019 Apr 1. PubMed DOI |
7. | mirRNA-365b promotes hepatocellular carcinoma cell migration and invasion by downregulating SGTB. Author: Tian Q1,2, Sun HF3, Wang WJ1,2, Li Q1,2, Ding J4, Di W1,2,5. Journal: Future Oncol. 2019 Apr 3. doi: 10.2217/fon-2018-0676. [Epub ahead of print] PubMed DOI |
8. | Retrospective comparison of stereotactic body radiotherapy versus intensity-modulated radiotherapy for stage III ultra-central squamous non-small-cell lung cancer. Author: Cong Y1, Xuan L2, Sun B2, Wang J2, Meng X2, Zhang J2, Xue J2, Liu J2, Shen G3, Wu S2. Journal: Future Oncol. 2019 Apr 5. doi: 10.2217/fon-2019-0061. [Epub ahead of print] PubMed DOI |
9. | Is anatomical resection necessary for early hepatocellular carcinoma? A single institution retrospective experience. Author: Shi F1, Zhou Z2, Huang X2, Liu Q3, Lin A1. Journal: Future Oncol. 2019 Apr 10. doi: 10.2217/fon-2019-0117. [Epub ahead of print] PubMed DOI |
10. | RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma. Author: Qin S1, Finn RS2, Kudo M3, Meyer T4, Vogel A5, Ducreux M6, Macarulla TM7, Tomasello G8, Boisserie F9, Hou J9, Li X10, Song J9, Zhu AX11. Journal: Future Oncol. 2019 Apr 10. doi: 10.2217/fon-2019-0097. [Epub ahead of print] PubMed DOI |
|
|